Search bioRxiv⌕ Search

Biology subjects

Elmarakeby, H. A.

Publications and source records attributed to Elmarakeby, H. A..

2 recordsLinked to original sources

Simulation and empirical evaluation of biologically-informed neural network performance

Biologically-informed neural networks (BiNNs) offer interpretable deep learning models for biological data, but the dataset characteristics required for strong performance remain poorly understood. For instance, we previously developed P-NET, a BiNN with an architecture based on the Reactome pathway database, and applied this model to predict metastatic status of patients with prostate cancer using somatic mutation and copy number information. It seems likely that including additional relevant signal - e.g., germline variation in this context - should improve model performance, but we currently lack a principled approach to assess whether BiNNs will successfully detect this signal. Here, we developed two simulation frameworks to evaluate the factors that influence BiNN performance - including signal type, signal strength, feature sparsity, and sample size - and empirically tested how integrating germline and somatic data affects the models ability to predict prostate cancer metastatic status. Simulations revealed that small sample size, weak signal strength, and especially extreme feature sparsity limit BiNN performance, and that the model preferentially uses linear over nonlinear signal. Empirically, P-NET performed poorly on sparse germline data, and while adding germline to somatic data did not improve prediction, it improved gene prioritization and model interpretation. Broadly, our simulation frameworks enable systematic evaluation of how dataset-level characteristics affect BiNN performance and provide a principled framework for benchmarking novel methods.

bioinformatics↗

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

While the introduction of immune checkpoint blockade (ICB) has dramatically improved clinical outcomes for patients with advanced melanoma, a significant proportion of patients develop resistance to therapy, and mechanisms of resistance are poorly elucidated in most cases. Further, while combination ICB has higher response rates and improved progression free survival compared to single agent therapy in the front line setting, there is significantly increased toxicity with combination ICB, and biomarkers to identify patients who would disproportionately benefit from combination therapy vs aPD-1 ICB are poorly characterized. To understand resistance mechanisms to single vs combination ICB therapy, we analyze whole-exome-sequencing (WES) of pre-treatment tumor and matched normals of 4 cohorts (n=140) of previously ICB-naive aPD-1 ICB treated patients. We find that high intratumoral genomic heterogeneity and low ploidy identify patients with intrinsic resistance to aPD-1 ICB. Comparing to a melanoma cohort from a pre-targeted therapy and ICB time period ("untreated" cohort), we find that genomic heterogeneity specifically predicts response and survival in the ICB treated cohorts, but not in the untreated cohort, while ploidy is also prognostic of overall survival in the "untreated" (by targeted therapy or ICB) group. To establish clinically actionable predictions, we optimize a simple decision tree using genomic ploidy and heterogeneity to identify with high confidence (90% PPV) a subset of patients with intrinsic resistance to and significantly worse survival on aPD1 ICB treatment. We then validate this model in independent cohorts, and further show that a significant proportion of patients predicted to have intrinsic resistance to single agent aPD-1 ICB respond to combination ICB, which suggests that nominated patients may benefit disproportionately from combination ICB. We further show that the features and predictions of the model are independent of known clinical features and previously nominated molecular biomarkers. These findings highlight the clinical and biological importance of genomic heterogeneity and ploidy, and sets a concrete framework towards clinical actionability, broadly advancing precision medicine in oncology.

cancer biology↗